Coordinated Specialty Care for First Episode Schizophrenia
neuroscienceCME WebcastPremiere Date: Thursday, January 5, 2017
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, January 5, 2018
|Jeffrey A. Lieberman, MD
President, American Psyichiatric Association
Lawrence C. Kolb Professor and Chairman, Department of Psychiatry
College of Physicians and Surgeons, Columbia University
Director, New York State Psychiatric Institute
Psychiatrist-in-Chief at New York Presbyterian Hospital & Columbia University Medical Center
New York, NY
This video is a replay of a plenary session from the 9th Annual Chair Summit Master Class for Neuroscience Professional Development held in Miami, Florida on September 15 – 17, 2016.
At the end of this CE activity, participants should be able to:
- Implement a proactive treatment plan to track metabolic changes and evaluate medication choices in individuals with schizophrenia.
- Expand the clinical assessment and treatment of cognitive and negative symptoms associated with schizophrenia.
This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.
Physicians, physician assistants, nurse practitioners, and other health care professionals with an interest in psychiatry, neurology, and the neurosciences.
CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Lieberman has disclosed that he receives research/grants from Alkermes*; Novartis Corporation/Vanda Pharmaceuticals*. He serves on the advisory board of Clintara; Intracellular Therapies, Inc.*; Pierre Fabre*. His other financial or material support include Repligen Corporation. *Dr. Lieberman received no direct financial compensation or salary support for participation in these research, consulting, or advisory board activities.
Howard Bliwise, MD (peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Jan Perez, CHCP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).